Wigginton, J M <br/><br/>
IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.  [electronic resource] 

 -  The Journal of clinical investigation  Jul 2001 
 - 51-62 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0021-9738 
<br/><br/><label>Standard No.: </label>10.1172/JCI10128  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--administration & dosage<br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Apoptosis--drug effects<br/>CD8-Positive T-Lymphocytes--immunology<br/>Carcinoma, Renal Cell--blood supply<br/>Combined Modality Therapy<br/>Drug Administration Schedule<br/>Endothelium, Vascular--drug effects<br/>Fas Ligand Protein<br/>Immunologic Factors--administration & dosage<br/>Injections, Intraperitoneal<br/>Interferon-gamma--physiology<br/>Interleukin-12--administration & dosage<br/>Kidney Neoplasms--blood supply<br/>Membrane Glycoproteins--deficiency<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Inbred C3H<br/>Mice, Knockout<br/>Mice, Mutant Strains<br/>Neoplasm Metastasis<br/>Neoplasm Transplantation<br/>Neovascularization, Pathologic--drug therapy<br/>Nephrectomy<br/>Recombinant Proteins--administration & dosage<br/>Specific Pathogen-Free Organisms<br/>fas Receptor--physiology